CFT7455, developed by C4 Therapeutics, is a potent degrader of Ikaros (IKZF1) and Aiolos (IKZF3), two transcription factors critical for multiple myeloma cell survival. This evidence concerns the gene IKZF1 and AL amyloidosis.